FDA Clears AI Tool To Detect Cancer In Bone Marrow
Scopio Labs, developer of Full-Field Digital Cell Morphology™ imaging and analysis platforms, as well as digital morphology, has been granted De Novo clearance by the U.S. Food and Drug Administration (FDA) for its Full-Field Bone Marrow Aspirate™ (FF-BMA) Application.
This marks a pivotal moment, establishing a new regulatory category for all-digital bone marrow aspirate analysis software. Prior, Vietnam showed off its success in using additive manufacturing to save a teenager with bone cancer.
Bone marrow cytology, the microscopic analysis of cells in bone marrow samples, remains a crucial diagnostic tool for a wide range of blood disorders. Hematologic malignancies account for about 10% of all diagnosed cancers in the U.S. and remain a leading cause of the global cancer burden.
Bone marrow aspirate (BMA) plays a vital role in diagnosing these and other hematologic conditions, both malignant and benign. However, traditional manual methods are labor-intensive, time-consuming, and heavily reliant on highly skilled hematopathologists to ensure accuracy.
Scopio’s FF-BMA Application transforms BMA analysis by introducing a fully digital workflow that seamlessly integrates with Scopio’s X100 and X100HT platforms. By combining high-resolution full-field imaging with a robust AI-powered decision support system (DSS), this solution aims to significantly benefit healthcare professionals and patients.
It enables hematopathologists to access and review bone marrow smears remotely (via a secure hospital network), reducing turnaround time, fostering collaboration, facilitating expert second opinions, and bolstering diagnostic confidence.
“We commend the FDA for acknowledging the essential need to support hematology experts in their complex work,” said Itai Hayut, CEO of Scopio Labs. “The approval of the FF-BMA Application arms them with robust decision support systems. By harnessing AI and Full-Field imaging, labs can streamline workflows, reduce operational costs, and enhance patient care.”
“Scopio’s FF-BMA Application addresses the urgent need for digital innovation amid the rising prevalence of hematologic conditions and healthcare demands,” said Adam Bagg, MD, a Professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and a lead investigator in the BMA study that was submitted to the FDA. “By optimising digital workflows and enabling unique remote review of entire smears, we are hopeful this technology can help enhance efficiency across the board.”
The FF-BMA Application is designed to assist trained operators in streamlining BMA review and reporting. It automates the detection and visualization of hematopoietic cells in stained smears, thus facilitating essential evaluations such as bone marrow smear quality assessment, blast cell and plasma cell estimation, and calculation of the myeloid to erythroid (M:E) ratio. This innovative tool aims to standardise BMA analysis, elevate diagnostic precision, and ultimately improve patient care.
What You Missed:
Additive Manufacturing Saved Teenager With Bone Cancer
Researchers Turn Metal Waste Into Catalyst For Hydrogen
Is AI Is Looking More Like A Band Aid Now?
Rever Automotive Builds And Tests BYD Buses In Thailand
Tesla Cuts More Than 10% Of Its Workforce
Tesla Settling Lawsuit Erodes Faith In Autonomous Driving
IoT Offers A Wealth Of Opportunities
High Household Debt In Dips Thailand Automotive Production And Sales
AST Begins Constructing Singapore Facility For High-End Substrates & Advanced Technologies
eVTOL Aircrafts May Dominate The Skies
WANT MORE INSIDER NEWS? SUBSCRIBE TO OUR DIGITAL MAGAZINE NOW!
CONNECT WITH US: LinkedIn, Facebook, Twitter
Letter to the Editor
Do you have an opinion about this story? Do you have some thoughts you’d like to share with our readers? APMEN News would love to hear from you!
Email your letter to the Editorial Team at [email protected]
